sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
|
picrotoxin
|
diazepam
|
EFFECT
|
2857099.xml
|
DDI-MedLine.d27.s0
|
DDI-MedLine.d27.s0.p0
|
Phenytoin: Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin.
|
Phenytoin
|
Etodolac
|
NONE
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s21
|
DDI-DrugBank.d219.s21.p0
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
fluconazole
|
sildenafil
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p78
|
Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
|
EQUETROTM
|
centrally acting drugs
|
ADVISE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s18
|
DDI-DrugBank.d94.s18.p0
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
quinidine
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p9
|
Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.
|
Methionine
|
gentamicin
|
EFFECT
|
L-Methionine_ddi.xml
|
DDI-DrugBank.d528.s2
|
DDI-DrugBank.d528.s2.p2
|
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
|
phenylbutazone
|
indomethacin
|
NONE
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s2
|
DDI-DrugBank.d488.s2.p22
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
Pronestyl
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p11
|
Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
|
nalidixic acid
|
warfarin
|
EFFECT
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s5
|
DDI-DrugBank.d427.s5.p4
|
The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
|
reserpine
|
sympathomimetics
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s3
|
DDI-DrugBank.d448.s3.p8
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
indinavir
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p6
|
Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.
|
Digoxin
|
digoxin
|
NONE
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s13
|
DDI-DrugBank.d499.s13.p1
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
nicotine
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p9
|
On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
|
erythromycin
|
bexarotene
|
MECHANISM
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s2
|
DDI-DrugBank.d467.s2.p13
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
metoclopramide
|
somatostatin analogs
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p512
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Sandimmune
|
theophylline
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p777
|
Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
|
Methadone
|
nevirapine
|
ADVISE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s42
|
DDI-DrugBank.d270.s42.p7
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
sodium colistemethate
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p9
|
Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
|
Antacid
|
atorvastatin
|
NONE
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s1
|
DDI-DrugBank.d140.s1.p0
|
Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
|
Robinul
|
potassium chloride
|
MECHANISM
|
Glycopyrrolate_ddi.xml
|
DDI-DrugBank.d510.s1
|
DDI-DrugBank.d510.s1.p0
|
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
|
docetaxel
|
ketoconazole
|
MECHANISM
|
Docetaxel_ddi.xml
|
DDI-DrugBank.d371.s1
|
DDI-DrugBank.d371.s1.p2
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
anesthetics
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p11
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
nifedipine
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p3
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
lorazepam
|
zonisamide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p824
|
Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
|
alcohol
|
hydrocodone
|
EFFECT
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s0
|
DDI-DrugBank.d396.s0.p18
|
therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
|
rifampin
|
carbamazepine
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s34
|
DDI-DrugBank.d382.s34.p5
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
trihexyphenidyl
|
amitriptyline
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p13
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylurea
|
sulfonamides
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p2
|
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
|
alosetron
|
protease inhibitors
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s10
|
DDI-DrugBank.d364.s10.p2
|
Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
|
quinidine
|
dehydroaripiprazole
|
NONE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s15
|
DDI-DrugBank.d509.s15.p8
|
Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
|
enoxacin
|
fenbufen
|
EFFECT
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s9
|
DDI-DrugBank.d395.s9.p4
|
The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
|
codeine
|
antihistamines
|
EFFECT
|
Guaifenesin_ddi.xml
|
DDI-DrugBank.d398.s0
|
DDI-DrugBank.d398.s0.p1
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
lincomycin
|
colistin
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p70
|
Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
|
Enalapril
|
thiazide-type diuretics
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s12
|
DDI-DrugBank.d107.s12.p1
|
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
|
retinyl acetate
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s2
|
DDI-MedLine.d12.s2.p5
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p0
|
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
|
barbiturates
|
psychotropic medications
|
NONE
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s1
|
DDI-DrugBank.d338.s1.p29
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
5HT3 Antagonists
|
ondansetron
|
NONE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p1
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
quinidine
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p9
|
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
|
antipsychotic agents
|
alcohol
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s3
|
DDI-DrugBank.d186.s3.p4
|
Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
|
Ethopropazine
|
alcohol
|
EFFECT
|
Ethopropazine_ddi.xml
|
DDI-DrugBank.d240.s0
|
DDI-DrugBank.d240.s0.p0
|
Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
|
digoxin
|
hydrochlorothiazide
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s7
|
DDI-DrugBank.d533.s7.p26
|
Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.
|
Itraconazole
|
hypoglycemic agents
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s27
|
DDI-DrugBank.d165.s27.p0
|
Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
|
Metoclopramide
|
fosfomycin
|
NONE
|
Fosfomycin_ddi.xml
|
DDI-DrugBank.d199.s0
|
DDI-DrugBank.d199.s0.p2
|
The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
|
glyburide
|
ketoconazole
|
NONE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s8
|
DDI-DrugBank.d172.s8.p6
|
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
|
neomycin
|
penicillin V
|
MECHANISM
|
Neomycin_ddi.xml
|
DDI-DrugBank.d330.s2
|
DDI-DrugBank.d330.s2.p0
|
Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
|
b-lactam antibiotics
|
cefdinir
|
MECHANISM
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s4
|
DDI-DrugBank.d420.s4.p5
|
NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
|
NSAIDs
|
cyclosporine
|
ADVISE
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s15
|
DDI-DrugBank.d82.s15.p0
|
Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release.
|
ouabain
|
PTX
|
EFFECT
|
2857198.xml
|
DDI-MedLine.d56.s8
|
DDI-MedLine.d56.s8.p0
|
There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
|
erythromycin
|
cisapride
|
EFFECT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s13
|
DDI-DrugBank.d397.s13.p0
|
The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.
|
18-MC
|
ibogaine
|
NONE
|
11085336.xml
|
DDI-MedLine.d110.s16
|
DDI-MedLine.d110.s16.p0
|
The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
|
ERGOMAR
|
triacetyloleandomycin
|
MECHANISM
|
Ergotamine_ddi.xml
|
DDI-DrugBank.d59.s0
|
DDI-DrugBank.d59.s0.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
citalopram
|
cyclosporin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p258
|
Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
|
Depen
|
Cuprimine
|
NONE
|
Auranofin_ddi.xml
|
DDI-DrugBank.d374.s1
|
DDI-DrugBank.d374.s1.p5
|
Acetazolamide may prevent the urinary antiseptic effect of methenamine.
|
Acetazolamide
|
methenamine
|
EFFECT
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s11
|
DDI-DrugBank.d368.s11.p0
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
5HT3 antagonist class
|
ADVISE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p24
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
phenothiazines
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p30
|
Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.
|
methotrexate
|
Kineret
|
NONE
|
Anakinra_ddi.xml
|
DDI-DrugBank.d275.s1
|
DDI-DrugBank.d275.s1.p0
|
Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
|
NSAIDs
|
Ponstel
|
NONE
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s0
|
DDI-DrugBank.d400.s0.p3
|
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
|
tricyclic antidepressants
|
hydrocodone
|
EFFECT
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s2
|
DDI-DrugBank.d396.s2.p4
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
chlordiazepoxide
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p7
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
Lorazepam
|
antidepressants
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p5
|
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
|
HALDOL
|
anesthetics
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s3
|
DDI-DrugBank.d186.s3.p6
|
Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.
|
ketoconazole
|
cisapride
|
ADVISE
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s9
|
DDI-DrugBank.d458.s9.p0
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
alfentanil
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p12
|
In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
|
PRINIVIL
|
indomethacin
|
NONE
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s9
|
DDI-DrugBank.d334.s9.p1
|
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
|
histamine H2-receptor antagonists
|
IRESSA
|
MECHANISM
|
Gefitinib_ddi.xml
|
DDI-DrugBank.d207.s7
|
DDI-DrugBank.d207.s7.p2
|
Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
|
ketoconazole
|
zaleplon
|
MECHANISM
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s22
|
DDI-DrugBank.d324.s22.p0
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
Calcidiol
|
Cholestyramine
|
NONE
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s0
|
DDI-DrugBank.d404.s0.p23
|
therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.
|
VIRACEPT
|
terfenadine
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s11
|
DDI-DrugBank.d340.s11.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
delavirdine
|
methadone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p453
|
In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
|
aminoglycoside
|
cephalosporins
|
EFFECT
|
Kanamycin_ddi.xml
|
DDI-DrugBank.d57.s0
|
DDI-DrugBank.d57.s0.p2
|
It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.
|
digoxin
|
ketoconazole
|
ADVISE
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s18
|
DDI-DrugBank.d458.s18.p0
|
Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
|
mefloquine
|
carbamazepine
|
EFFECT
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s16
|
DDI-DrugBank.d94.s16.p5
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
azoles
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p1
|
Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
|
Vitamin D
|
digitalis
|
ADVISE
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s7
|
DDI-DrugBank.d404.s7.p2
|
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
|
ouabain
|
Innovar
|
EFFECT
|
1167743.xml
|
DDI-MedLine.d23.s2
|
DDI-MedLine.d23.s2.p0
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
protease inhibitors
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p31
|
Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.
|
sympathomimetic amines
|
monoamine oxidase inhibitors
|
EFFECT
|
Benzphetamine_ddi.xml
|
DDI-DrugBank.d477.s0
|
DDI-DrugBank.d477.s0.p0
|
Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
|
lorazepam
|
alcohol
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s0
|
DDI-DrugBank.d18.s0.p4
|
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
|
Theophylline
|
ciprofloxacin
|
NONE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s16
|
DDI-DrugBank.d123.s16.p1
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
hypnotics
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p16
|
Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
|
ENABLEX
|
flecainide
|
ADVISE
|
Darifenacin_ddi.xml
|
DDI-DrugBank.d459.s1
|
DDI-DrugBank.d459.s1.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
disopyramide
|
alfentanyl
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p41
|
INOmax has been administered with tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.
|
INOmax
|
dobutamine
|
NONE
|
Nitric Oxide_ddi.xml
|
DDI-DrugBank.d183.s1
|
DDI-DrugBank.d183.s1.p2
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
sildenafil
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p9
|
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
|
NSAIDs
|
anticoagulant
|
NONE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s2
|
DDI-DrugBank.d249.s2.p6
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
delavirdine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p6
|
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
|
phenytoin
|
calcitriol
|
MECHANISM
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s2
|
DDI-DrugBank.d384.s2.p11
|
The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
|
proton pump inhibitors
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s13
|
DDI-DrugBank.d48.s13.p5
|
There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
|
cisapride
|
erythromycin
|
MECHANISM
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s13
|
DDI-DrugBank.d397.s13.p5
|
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
furosemide
|
thiazides
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s10
|
DDI-DrugBank.d328.s10.p5
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
niacinamide
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p16
|
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
|
Mefloquine
|
H1-blocking agents
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s9
|
DDI-DrugBank.d220.s9.p4
|
Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
|
triazolam
|
midazolam
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s23
|
DDI-DrugBank.d124.s23.p5
|
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
|
docetaxel
|
troleandomycin
|
MECHANISM
|
Docetaxel_ddi.xml
|
DDI-DrugBank.d371.s1
|
DDI-DrugBank.d371.s1.p4
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
amiodarone
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p1
|
In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
|
warfarin
|
rofecoxib
|
EFFECT
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s32
|
DDI-DrugBank.d210.s32.p0
|
Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
ritonavir
|
cisapride
|
NONE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s12
|
DDI-DrugBank.d237.s12.p8
|
Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.
|
L-arginine
|
ibuprofen
|
MECHANISM
|
L-Arginine_ddi.xml
|
DDI-DrugBank.d95.s1
|
DDI-DrugBank.d95.s1.p2
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.